Loading news...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 40,985 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus.
MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
GSA Capital Partners LLP reduced its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) by 69.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,251 shares of the company's stock after selling 18,800 shares during the quarter. GSA Capital
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026.
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
TORONTO--(BUSINESS WIRE)--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome.
TORONTO--(BUSINESS WIRE)--Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.
Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year.